Patents by Inventor Kenneth J. Simon
Kenneth J. Simon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220397571Abstract: The invention relates to methods and reagents for analyzing samples for the presence of JC virus antibodies.Type: ApplicationFiled: March 25, 2022Publication date: December 15, 2022Inventors: Leonid GORELIK, Kenneth J. SIMON, Meena SUBRAMANYAM, Mia Marie RUSHE
-
Patent number: 11287423Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.Type: GrantFiled: October 7, 2019Date of Patent: March 29, 2022Assignee: Biogen MA Inc.Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
-
Patent number: 11230601Abstract: Provided herein are antibodies which bind to latency-associated peptide (LAP) of TGF-?1 and are characterized by particular functional features, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.Type: GrantFiled: October 10, 2018Date of Patent: January 25, 2022Assignee: Tilos Therapeutics, Inc.Inventors: Barbara S. Fox, Randall Burton, Stavros Kopsiaftis, Xiufeng Song, Patricia Rao, Kenneth J. Simon, Jessie M. English
-
Publication number: 20220017612Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.Type: ApplicationFiled: September 2, 2021Publication date: January 20, 2022Inventors: Randall Burton, Jessie M. English, Barbara S. Fox, Stavros Kopsiaftis, Yacob Gomez Llorente, Renee Moore, Patricia Rao, Giovanna Scapin, Kenneth J. Simon, Haihong Zhou
-
Patent number: 11130802Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.Type: GrantFiled: October 9, 2019Date of Patent: September 28, 2021Assignees: Tilos Therapeutics, Inc., Merck Sharp & Dohme Corp.Inventors: Randall Burton, Jessie M. English, Barbara S. Fox, Stavros Kopsiaftis, Renee Moore, Patricia Rao, Kenneth J. Simon
-
Publication number: 20210102939Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.Type: ApplicationFiled: October 7, 2019Publication date: April 8, 2021Inventors: Leonid GORELIK, Kenneth J. SIMON, Meena SUBRAMANYAM, Mia Marie RUSHE
-
Publication number: 20200140530Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.Type: ApplicationFiled: October 9, 2019Publication date: May 7, 2020Inventors: Randall BURTON, Jessie M. ENGLISH, Barbara S. FOX, Stavros KOPSIAFTIS, Yacob GOMEZ LLORENTE, Renee MOORE, Patricia RAO, Giovanna SCAPIN, Kenneth J. SIMON, Haihong ZHOU
-
Patent number: 10444234Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.Type: GrantFiled: March 8, 2016Date of Patent: October 15, 2019Assignee: BIOGEN MA INC.Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
-
Publication number: 20190144549Abstract: Provided herein are antibodies which bind to latency-associated peptide (LAP) of TGF-?1 and are characterized by particular functional features, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.Type: ApplicationFiled: October 10, 2018Publication date: May 16, 2019Inventors: Barbara S. FOX, Randall BURTON, Stavros KOPSIAFTIS, Xiufeng SONG, Patricia RAO, Kenneth J. SIMON, Jessie M. ENGLISH
-
Patent number: 9745376Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.Type: GrantFiled: July 28, 2014Date of Patent: August 29, 2017Assignees: Biogen MA Inc., The Regents of the University of CaliforniaInventors: Shelia M. Violette, Paul Henry Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
-
Publication number: 20160187337Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.Type: ApplicationFiled: March 8, 2016Publication date: June 30, 2016Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
-
Patent number: 9316641Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.Type: GrantFiled: January 11, 2011Date of Patent: April 19, 2016Assignee: BIOGEN MA INC.Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
-
Publication number: 20150140609Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Q mediated diseases.Type: ApplicationFiled: July 28, 2014Publication date: May 21, 2015Inventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
-
Patent number: 8992924Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: GrantFiled: May 17, 2011Date of Patent: March 31, 2015Assignee: Biogen Idec MA Inc.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Publication number: 20140294809Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: ApplicationFiled: January 22, 2014Publication date: October 2, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W.T. Van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Publication number: 20130022961Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.Type: ApplicationFiled: January 11, 2011Publication date: January 24, 2013Inventors: Leonid Gorelik, Kenneth J. Simon, Meena Subramanyam, Mia Marie Rushe
-
Publication number: 20120251532Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.Type: ApplicationFiled: April 10, 2012Publication date: October 4, 2012Applicants: The Regents of the University of California, a California corporation, BIOGEN IDEC MA INC.Inventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
-
Patent number: 8153126Abstract: Monoclonal antibodies that specifically bind to ?v??. Also included are methods of using these antibodies to treat mammals having or at risk of having ?v?6-mediated diseases, or to diagnose ?V?6-mediated diseases.Type: GrantFiled: October 29, 2008Date of Patent: April 10, 2012Inventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
-
Publication number: 20110305629Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: ApplicationFiled: May 17, 2011Publication date: December 15, 2011Applicant: BIOGEN IDEC MA INC.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W.T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Patent number: 7943742Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: GrantFiled: July 10, 2006Date of Patent: May 17, 2011Assignee: Biogen Idec MA Inc.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy